Verastem (VSTM) Q2 FY26 earnings call

Verastem delivered a strong second quarter, marked by a significant commercial rebound for AvMap Gifex India Copac, driven by increased physician confidence and earlier treatment initiation. The company also substantially strengthened its balance sheet through non-dilutive financing and a milestone payment, providing strategic flexibility. Progress in the VS-7375 pipeline, including fast-track designation and initiation of Phase II studies, positions the company for key data readouts and future development.